Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

@article{Modi2007CombinationOT,
  title={Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.},
  author={Shanu Modi and Alison T Stopeck and Michael S Gordon and David Mendelson and David B. Solit and Rochelle Bagatell and Weining Ma and Jennifer J. Wheler and Neal Rosen and Larry Norton and Gillian F. Cropp and Robert Wood Johnson and Alison L. Hannah and Clifford A. Hudis},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 34},
  pages={5410-7}
}
PURPOSE This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes. PATIENTS AND METHODS Patients with an advanced solid tumor progressing during standard therapy were eligible. Patients were treated with weekly trastuzumab followed by intravenous tanespimycin, assessed in escalating dose levels. RESULTS Twenty-five… CONTINUE READING
125 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 125 extracted citations

Similar Papers

Loading similar papers…